Argenx has posted positive Phase 3 results for its blockbuster antibody Vyvgart in myositis, a group of inflammatory muscle diseases — opening a new market for one of biotech’s biggest recent successes.

In the ALKIVIA study, Vyvgart Hytrulo (efgartigimod, given subcutaneously) delivered a 15.4-point greater mean improvement than placebo on the Total Improvement Score after 52 weeks. Shares rose more than 13%.

What myositis does

The idiopathic inflammatory myopathies are autoimmune diseases in which the immune system attacks muscle, producing progressive weakness that affects the muscles closest to the trunk first — so patients struggle to climb stairs, rise from chairs and lift their arms.

In severe cases the muscles of swallowing and breathing are involved, which is what makes these conditions dangerous rather than merely disabling.

How Vyvgart works

Efgartigimod blocks FcRn, the receptor that recycles antibodies and keeps them circulating for weeks rather than hours.

Blocking it accelerates clearance of IgG antibodies generally — including the pathogenic autoantibodies driving disease. The approach does not target a specific autoantibody; it lowers the whole class, which works in any condition where an excess of one is causing the damage.

That generality is why the drug has expanded across indications rather than remaining in one.

The results, and where they were strongest

The company described a “rapid and sustained benefit” starting around week four and lasting a year while patients tapered off steroids.

The trial covered forms including immune-mediated necrotising myopathy (IMNM) — an aggressive disease that breaks down muscle cells, affecting roughly 20,000 patients with no approved treatments — and dermatomyositis.

The effect was strong in IMNM. In dermatomyositis the improvement was meaningful but not statistically significant.

Why the split result is informative rather than disappointing

The difference between the two groups fits the biology, which strengthens rather than undermines the finding.

IMNM is driven substantially by specific autoantibodies attacking muscle directly, and antibody levels track with disease activity. A therapy that accelerates antibody clearance should work there, and it did.

Dermatomyositis involves autoantibodies too, and its pathology has a larger contribution from other mechanisms, including interferon signalling and damage to small blood vessels supplying muscle and skin. A drug removing antibodies would address part of that picture rather than all of it.

A result that is strong where the mechanism predicts and weaker where it does not is more credible than uniform benefit across biologically distinct conditions.

The steroid point

Benefit sustained while patients tapered off steroids is the practically important framing.

Corticosteroids are the backbone of myositis treatment and cause substantial cumulative harm — bone loss, diabetes, infection risk, cataracts. They also cause muscle weakness themselves, which in a disease defined by muscle weakness makes the treatment difficult to distinguish from the disease.

“For people living with myositis, the goal is straightforward: regain strength and function, and get off long-term steroids,” said University of Pittsburgh myositis researcher Rohit Aggarwal.

What it means commercially

Vyvgart is already approved for generalised myasthenia gravis and has expanded into chronic inflammatory demyelinating polyneuropathy, generating about $2.9 billion in revenue in the first half of 2026.

The pattern is a platform drug moving methodically through autoantibody-mediated diseases. Each indication is individually modest and shares manufacturing, safety data and prescriber familiarity — and analysts called the data a meaningful expansion opportunity for the roughly $60-billion company.

The competitive context

FcRn blockade is no longer a single-company mechanism, with several agents in development and approved across overlapping indications.

What the Total Improvement Score actually measures

The endpoint deserves explanation, because a 15.4-point difference means nothing without knowing the scale.

The Total Improvement Score is a composite developed specifically for myositis trials, combining six measures: physician and patient global assessments of disease activity, a manual muscle strength test, a physical function questionnaire, muscle enzyme levels in blood, and an assessment of activity in organs beyond muscle.

Combining them addresses a real problem — myositis affects strength, function, laboratory markers and other organs, and no single measure captures whether a patient is better. The composite converts improvement across those domains into a single score, with thresholds defining minimal, moderate and major improvement.

A 15.4-point mean difference over placebo therefore represents improvement distributed across several domains rather than a shift in one convenient number, which is a more demanding thing to achieve and a more meaningful one to report.

Argenx’s advantage is being first and broadest — each new indication deepens the evidence base and the prescribing habit, which in autoimmune neurology is a substantial barrier for a later entrant to overcome. Clinical and business news, not medical or investment advice.